DSSG Group: Lung

Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation

This Phase 2 study will evaluate the efficacy and safety of MRTX849 on its own and in combination with pembrolizumab.

Extensive-Stage Small Cell Lung Cancer
– Newly diagnosed ES-SCLC
– ECOG 0-1
– No active brain metastases requiring treatment
– No autoimmune or neurologic paraneoplastic syndromes
– No pneumonitis or interstitial lung disease

This trial is for people who have small-cell lung cancer (SCLC) that has spread to both lungs or other parts of the body. This type of lung cancer is called extensive-stage SCLC (ES-SCLC).
This trial is testing MK-7684A compared with Atezolizumab when given with standard chemo in people with ES-SCLC.
This trial is being done to:
• Test the safety of MK-7684A plus chemo. See how well MK-7684A plus chemo works compared to Atezolizumab plus chemo.
• See if participants who get of MK-7684A plus chemo have a better quality of life, compared to those who get Atezolizumab plus chemo.

previously treated metastatic NSCLC with a KRAS G12C mutation.

To evaluate the efficacy of the investigational agent MRTX849 (adagrasib) versus docetaxel in patients who have been previously treated for metastatic NSCLC with a KRAS G12C mutation.

Participants with previously untreated Stage IV Non-Small Cell Lung Cancer.

The objective of the trial is to confirm the dose safety of combination relatlimab and nivolumab plus chemo and to compare the progression free survival for patients with untreated stage IV Non-Small Cell Lung Cancer or Recurrent Non-small Cell Lung Cancer.

This clinical trial is recruiting people with non-small cell lung cancer (NSCLC) that cannot be removed through surgery or that has spread to other parts of the body.

AcceleRET-Lung: A clinical trial to compare a medicine called pralsetinib with standard-of-care chemotherapy treatments in people with non-small cell lung cancer (NSCLC).

inoperable, early stage, high-risk ultracentrally located lung tumours.

The purpose of the study is to determine the safety of the radiation therapy treatment regimen in terms of side effects experienced within one year after treatment which are related to the radiation therapy.

thoracic cancer and a COVID infection

This registry collects data on patients who have a thoracic cancer and are infected with COVID-19

locally advanced or metastatic non-small cell lung cancer previously treated with systemic cytotoxic therapy (or ineligible), and an immune checkpoint inhibitor (as monotherapy or in combination with systemic cytotoxic chemotherapy, or ineligible)

This study is designed to identify the target Non-Small Cell Lung Cancer (NSCLC) population(s) that over express c-Met (c-Met+) best suited for telisotuzumab vedotin therapy in the second line or third line setting (Stage 1) and then to expand the group(s) to further evaluate efficacy in the selected population(s) (Stage 2).